Insulet (PODD) Saham Harga
Insulet Harga
Pendapatan tumbuh 41,6% per tahun selama 19 tahun terakhir menjadi 2,71 miliar USD. Laba per saham tumbuh 81,5% per tahun selama 7 tahun terakhir. margin bersih Insulet saat ini 9,1%, naik dari 1,5% beberapa tahun lalu. Target harga median analis adalah 180,00 USD, di atas harga saat ini sebesar 33,6%. Dari 33 analis, 20 merekomendasikan beli — konsensus keseluruhan Beli.
Harga saham Insulet
Model bisnis dan analisis saham Insulet
Pertanyaan yang sering diajukan tentang saham Insulet
The business model of Insulet Corp revolves around the development and commercialization of innovative medical devices for individuals with diabetes. Insulet is known for its flagship product, the Omnipod Insulin Management System, which is a tubeless insulin pump. This system is designed to provide continuous subcutaneous insulin delivery with customizable insulin plans and improved convenience for users. Insulet Corp focuses on helping diabetes patients manage their condition effectively and ensuring a better quality of life. With their unique and advanced technology, Insulet continues to make significant contributions to the diabetes healthcare industry.
Insulet Corp is primarily active in the healthcare industry, specifically in the medical devices sector.
The main competitors of Insulet Corp in the market are Medtronic plc, Tandem Diabetes Care, Inc., and Dexcom, Inc. These companies operate in the same industry sector and offer similar products and services. Medtronic plc is a multinational medical device company, Tandem Diabetes Care, Inc. specializes in insulin pumps, and Dexcom, Inc. provides continuous glucose monitoring systems. These competitors pose challenges to Insulet Corp in terms of market share and product innovation. Competing with these industry leaders, Insulet Corp strives to differentiate itself through its Omnipod System, a unique tubeless insulin delivery system.
Insulet Corp is a leading medical technology company headquartered in Massachusetts, United States. Founded in 2000, Insulet is focused on improving the lives of individuals with diabetes through the development and manufacturing of innovative insulin delivery systems. The company is renowned for its flagship product, the Omnipod Insulin Management System, which offers patients a unique tubeless and wireless insulin pump experience. Insulet has a rich history of achievement and continuous growth, earning recognition for its dedication to patient-centric solutions. With a strong commitment to advancing diabetes care, Insulet Corp has positioned itself as a trusted and reliable provider in the medical technology industry.
Insulet Corp has achieved several significant milestones in its history. One of the notable achievements is the development and introduction of the Omnipod System, a tubeless insulin delivery system that has revolutionized diabetes management. This innovative product has gained wide acceptance and has positively impacted the lives of many patients. Additionally, Insulet Corp has successfully expanded its global presence, securing regulatory approvals in various countries and establishing partnerships with healthcare providers worldwide. The company has also demonstrated consistent financial growth and market success, solidifying its position as a leader in the diabetes technology industry.
Insulet Corp primarily operates in the United States, Canada, Europe, and the Middle East.
Insulet Corp is a renowned company in the stock market known for its values and corporate philosophy. The company aims to improve the lives of people with diabetes through innovative and reliable technologies. Insulet Corp values patient-centricity by providing user-friendly and discreet products like the Omnipod System. Their corporate philosophy revolves around continuous innovation, teamwork, and a commitment to making a difference in diabetes management. Insulet Corp's vision is to empower individuals with diabetes to live life to the fullest, offering them better control, flexibility, and convenience. With a dedicated focus on diabetes care, Insulet Corp sets itself apart in the market, making it a highly regarded company among investors.
Analis saat ini menetapkan target harga rata-rata 185,18 USD untuk saham Insulet (median: 180,00 USD), yaitu +37,4 % terhadap harga terbaru. Konsensus didasarkan pada 33 peringkat analis.
33 analis saat ini menilai saham Insulet: 20 merekomendasikan beli, 13 tahan, dan 0 jual. Untuk 2026, analis memperkirakan Insulet menghasilkan pendapatan 3,29 miliar USD dan laba per saham 6,62 USD.
Dengan kurs saat ini, saham Insulet diperdagangkan pada 120,27 EUR (134,77 USD).
Saham Insulet (PODD) tercatat di 5 bursa, termasuk: NASDAQ (PODD), SIX (Zürich) (GOV.SW), Frankfurt (GOV.F), München (GOV.MU), Düsseldorf (GOV.DU).
Insulet Corporation is a company specializing in the development and manufacturing of personalized insulin delivery systems. The company is headquartered in Acton, Massachusetts, USA and was founded in 2000.
Pendapatan diperkirakan dari Insulet adalah 3,29 miliar USD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba diperkirakan dari Insulet adalah 467,51 Juta. USD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) Insulet saat ini adalah 20,37. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Insulet.
Rasio harga-terhadap-penjualan (PSR) Insulet saat ini adalah 2,89. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Insulet.
Skor Kualitas AlleAktien untuk Insulet adalah 6/10.
ISIN dari Insulet adalah US45784P1012. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
WKN dari Insulet adalah A0MQX8. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.
Ticker dari Insulet adalah PODD. Simbol ticker digunakan untuk memperdagangkan saham Insulet di bursa saham.
Saham Insulet
Kelompok Peer Insulet
Insulet Ticker
Insulet FIGI
Semua metrik fundamental dan analisis mendalam Insulet
Analisis saham kami untuk saham Insulet mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Insulet. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.